

**UNITED STATES DISTRICT COURT
DISTRICT OF COLORADO
Denver**

AMGEN INC., *et al.*,

Plaintiffs,

v.

GAIL MIZNER, MD, in her official
capacity as Chair of the Colorado
Prescription Drug Affordability Review
Board, *et al.*,

Defendants.

**Civil Action
No. 1:24-cv-810-NYW-SBP**

**PLAINTIFFS' NOTICE OF RESCHEDULING
OF UPL RULEMAKING HEARING**

Plaintiffs Amgen Inc., Immunex Corporation, and Amgen Manufacturing, Limited submit this notice to inform the Court that the first rulemaking hearing to establish an upper payment limit for Enbrel, previously scheduled for March 7, 2025, has been rescheduled for April 11, 2025. *See* Exhibit A.

Dated: February 28, 2025

Cliff Stricklin
(Colo. Bar No. 39725)
KING & SPALDING LLP
1401 Lawrence Street, Suite 1900
Denver, CO 80202
(720) 535-2300
cstricklin@kslaw.com

Respectfully submitted,

/s/ Paul Alessio Mezzina

Ashley C. Parrish
(D.C. Bar No. 464683)
Paul Alessio Mezzina
(D.C. Bar No. 999325)
Kelly Nicole Reeves
(D.C. Bar No. 471923)
Brian A. Bohnenkamp
(D.C. Bar No. 982213)
Alexander Kazam
(D.C. Bar No. 1708188)
KING & SPALDING LLP
1700 Pennsylvania Avenue NW
Washington, DC 20006
(202) 737-0500
aparrish@kslaw.com
pmezzina@kslaw.com
nreeves@kslaw.com
bbohenkamp@kslaw.com
akazam@kslaw.com

Counsel for Plaintiffs

EXHIBIT A



COLORADO

Department of
Regulatory Agencies

Colorado Office of Policy, Research &
Regulatory Reform



Detailed Rulemaking Information

Department/Agency

Department: Department of Regulatory Agencies

Rulemaking

Agency: Insurance

Proposed Rule Changes

Rule Type: New Rules

Title or Subject: UPPER PAYMENT LIMITS

Short

Description: NEW HEARING DATE: Upper payment limit

CCR Number: 3 CCR 702-9

Statutory sections 10-16-1403(1)(c), 10-16-1403(5), 10-16-1407(1)(a), and 10-16-1407(5), 10-16-

Authority: 1407(6), C.R.S.

Website for

Current Agency

Rules:

Subject WEBINAR ONLY: The purpose of this rule is to establish an upper payment limit for the

Matter/Purpose: prescription drug, Enbrel, pursuant to section 10-16-1407, C.R.S., and part 4.1 of these rules. The Board performed an affordability review of Enbrel and determined it was unaffordable for Colorado consumers pursuant to section 10-16-1406, C.R.S., and part 3 of these rules.

Colorado

Register

Publish Date: 12/25/2024

Text of

Proposed

Changes: [Draft Enbrel Proposed Rule - Part 4.doc](#) (45K, Microsoft Word)

Submitted for

Review: 12/13/2024

Rulemaking Hearing

Hearing Date: Friday, April 11, 2025 10:00 am

Hearing

Covers: Single Rule

Hearing

Location: Webinar Only

Hearing Notes: This Permanent Rulemaking Hearing will be held via WEBINAR ONLY. Please register here to attend the hearing via webinar on April 11, 2025:

<https://us06web.zoom.us/meeting/register/tZEkcumhrz8qGNQvJHFJh18quqSZKYadcE-S#/registration>

The Board will receive oral testimony regarding this permanent rule on April 11, 2025, beginning at 10:00 AM. Please visit <https://doi.colorado.gov/insurance-products/health-insurance/prescription-drug-affordability-review-board> for additional information related to hearing dates and deadlines for written submissions regarding this rule.

Contact Information

Public Contact

Name: Jill Mullen

Title: Policy Advisor

Email: jill.mullen@state.co.us

Phone: 720-556-4952

Subject Information

Related Subject Area(s): Insurance

Review

Review Date: 12/31/2024

Review

Outcome: Cost-Benefit Analysis Required

Review

Findings: Cost-benefit analysis required as requested.

Deadline for Monday, December 30th, 2024

Public Cost-Benefit

Analysis

Request:

The deadline for public cost-benefit analysis requests has passed.

Cost-Benefit Analysis

Cost-Benefit Analysis Pending



[New Search](#)

1560 Broadway, Suite 1550, Denver, CO 80202 [Email](#)

•

© 2025 State of Colorado